Publicaciones en las que colabora con Miguel Ángel Abellanas Sánchez (11)

2024

  1. Nigrostriatal degeneration determines dynamics of glial inflammatory and phagocytic activity

    Journal of Neuroinflammation, Vol. 21, Núm. 1

2023

  1. Microglia and astrocyte activation is region-dependent in the α-synuclein mouse model of Parkinson's disease

    GLIA, Vol. 71, Núm. 3, pp. 571-587

2021

  1. Expression of endothelial nox5 alters the integrity of the blood-brain barrier and causes loss of memory in aging mice

    Antioxidants, Vol. 10, Núm. 8

  2. Gut microbial dysbiosis after traumatic brain injury modulates the immune response and impairs neurogenesis

    Acta Neuropathologica Communications, Vol. 9, Núm. 1

2020

  1. Cannabinoid receptor type 2 as a therapeutic target for Parkinson’s disease

    Diagnosis and Management in Parkinson’s Disease: The Neuroscience of Parkinson’s Disease, Volume 1 (Elsevier), pp. 557-573

  2. Cb2 receptors and neuron–glia interactions modulate neurotoxicity generated by magl inhibition

    Biomolecules, Vol. 10, Núm. 8, pp. 1-15

  3. Mecanismos inmunosupresores de la microglía del mesencéfalo en modelos de neuroinflamación y daño neurológico

    Mecanismos inmunosupresores de la microglía del mesencéfalo en modelos de neuroinflamación y daño neurológico

2019

  1. Dopamine receptor D3 expression is altered in CD4+ T-cells from Parkinson's disease patients and its pharmacologic inhibition attenuates the motor impairment in a mouse model

    Frontiers in Immunology, Vol. 10, Núm. MAY

  2. Midbrain microglia mediate a specific immunosuppressive response under inflammatory conditions

    Journal of Neuroinflammation, Vol. 16, Núm. 1

2018

  1. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

    Biochemical Pharmacology, Vol. 157, pp. 67-84

  2. The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia

    Neurobiology of Disease, Vol. 118, pp. 64-75